DDMS is a mechanism-based, irreversible inhibitor that has about 10-fold selectivity for the CYP4A11 (CYP450 4A2) enzyme which predominantly synthesizes 20-HETE in the mammalian kidney. DDMS administration in whole anesthetized rats (10 mg/kg) largely ablates the hypotension and vasodilation induced by nitric oxide donors such as NONOates. Biosynthesis of 20-HETE from arachidonic acid by the CYP4A11 (cytochrome P450 4A) isoforms is an important component of vascular homeostasis, especially in renal circulation.
Specifications and Purity: ≥98%
Molecular Formula: C13H23Br2NO3S
Molecular Weight: 433.2
PubChem CID: 11212661
Isomeric SMILES: CS(=O)(=O)NC(=O)CCCCCCCCCC=C(Br)Br
Related Documents: https://aladdin-for-icloud-store.oss-cn-hangzhou.aliyuncs.com/aladdinsci/pdp/sds/1/D344397-SCI_5e40523e424ebcb28a105360d7446631.pdf
- UPC:
- 41111917
- Condition:
- New
- HazmatClass:
- No
- WeightUOM:
- LB
- MPN:
- D344397-25mg
- CAS:
- 206052-03-1
- Product Size:
- 25mg
- Precautionary Statement Codes:
- P264
akash.verma@cenmed.com
(732) 447-1115





